AEON Biopharma, Inc. (AEON) — Cash Flow-to-Debt Ratio
AEON Biopharma, Inc. (AEON) has a Cash Flow-to-Debt Ratio of -0.09x as of September 2025, meaning its operating cash flow of $-2.60 Million could theoretically repay 0% of its total liabilities ($28.61 Million) in one year. See AEON working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
AEON Biopharma, Inc. Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for AEON Biopharma, Inc. across 6 annual periods. Also explore AEON Biopharma, Inc. annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for AEON Biopharma, Inc. (2019–2024)
Year-by-year debt coverage analysis for AEON Biopharma, Inc.. For market capitalisation and broader financial context, see how much is AEON Biopharma, Inc. worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.64x | $-20.29 Million | $31.71 Million | ▼ -113.9% |
| 2023 | -0.30x | $-47.83 Million | $159.89 Million | ▼ -136.4% |
| 2022 | -0.13x | $-35.58 Million | $281.19 Million | ▼ -2.5% |
| 2021 | -0.12x | $-28.43 Million | $230.26 Million | ▼ -192.9% |
| 2020 | -0.04x | $-9.46 Million | $224.45 Million | ▲ +83.0% |
| 2019 | -0.25x | $-44.73 Million | $180.22 Million | — |